Antibodies

20 Dec 2019 European Commission approves Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
20 Dec 2019 MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA
20 Dec 2019 Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody
20 Dec 2019 GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis
20 Dec 2019 Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration
20 Dec 2019 NeuClone Completes Dosing in Phase I Clinical Trial of Stelara® (ustekinumab) Biosimilar Candidate
19 Dec 2019 FDA Grants Accelerated Approval to Astellas’ and Seattle Genetics’ PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer
19 Dec 2019 Daiichi Sankyo Launches Antitumor Agent Bevacizumab Biosimilar for Intravenous Drip Infusions “Daiichi Sankyo” in Japan
18 Dec 2019 OBI Pharma Announces Initiation of a Phase 1/2 Study of Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
18 Dec 2019 BioInvent Has Entered Into a Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1206 in Combination With KEYTRUDA® in Advanced Solid Tumors
17 Dec 2019 Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH
17 Dec 2019 Alligator Bioscience: First Patient Dosed With ATOR-1017 Developed for Metastasized Cancer
17 Dec 2019 ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
17 Dec 2019 Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
16 Dec 2019 Meiji Seika Pharma and Dong-A Socio Holdings Initiate Phase I Clinical Trial of DMB-3115, a Ustekinumab Biosimilar Candidate
13 Dec 2019 Novartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD
13 Dec 2019 Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy
13 Dec 2019 CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
13 Dec 2019 CHMP Grants Positive Opinion for Expanded Use of Darzalex (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
13 Dec 2019 aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923
13 Dec 2019 Zhejiang Medicine and Ambrx Present Positive Top Line Data from a Phase 1a/1b Clinical Trial of ARX788 in Metastatic HER2 Positive Breast Cancer
13 Dec 2019 Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment
13 Dec 2019 Silverback Therapeutics Announces Preclinical Data at 2019 San Antonio Breast Cancer Symposium (SABCS) Supporting Development of SBT6050 as a Single Agent and in Combination with Trastuzumab for the Treatment of HER2-Expressing Malignancies
13 Dec 2019 Innate Pharma provides update on lacutamab TELLOMAK trial
13 Dec 2019 Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top